Vaxart (VXRT) Reports First Patient Enrollment in Phase 1b Norovirus Boosting Regimen Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Vaxart (VXRT) Reports First Patient Enrollment in Phase 1b Norovirus Boosting Regimen Study
May 3, 2021 5:07 PM EDT
Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today at Vaxarts key opinion leader event that new data obtained from its Phase I COVID-19 trial added to the evidence suggesting that VXA-CoV2-1, the companys first COVID-19 oral vaccine construct that triggers mucosal immunity and includes both the S and the N SARS-Cov-2 proteins, has broad cross-coronavirus activity.
We have previously announced study data showing that our oral vaccine could be as protective as the... More
May 3, 2021 9:30 AM EDT
Today's Pre-Open Stock Movers
Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) 33% HIGHER; adds to recent momentum gains.
Meredith Corporation (NYSE: MDP) 12.5% HIGHER; today announced that it has agreed to sell its Local Media Group ("LMG") to Gray Television, Inc. (NYSE: GTN) for $2.7 billion in cash and will focus exclusively on its... More
May 3, 2021 8:03 AM EDT
Vaxart (NASDAQ: VXRT) reported Q1 EPS of ($0.14), versus ($0.02) reported last year. Revenue for the quarter came in at $506 thousand, versus $2.9 million reported last year.
For earnings history and earnings-related data on Vaxart (VXRT) click here.
...
More
